297 related articles for article (PubMed ID: 16904418)
1. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Terlinden R; Uragg H; Göhler K; Kneip C
Contraception; 2006 Sep; 74(3):239-44. PubMed ID: 16904418
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
Bonn M; Eydeler U; Barkworth M; Rovati LC
Arzneimittelforschung; 2009; 59(12):651-8. PubMed ID: 20108652
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
Zahradnik HP; Hanjalic-Beck A
Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
[TBL] [Abstract][Full Text] [Related]
5. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
Winkler UH; Röhm P; Höschen K
Contraception; 2010 May; 81(5):391-400. PubMed ID: 20399945
[TBL] [Abstract][Full Text] [Related]
6. Chlormadinone acetate (CMA) in oral contraception--a new opportunity.
Bouchard P
Eur J Contracept Reprod Health Care; 2005; 10 Suppl 1():7-11. PubMed ID: 16356876
[TBL] [Abstract][Full Text] [Related]
7. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Griffith SG; Dai Y
Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
[TBL] [Abstract][Full Text] [Related]
8. Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass.
Uras R; Orrù M; Etzi R; Peppi G; Marotto MF; Pilloni M; Zedda P; Lello S; Melis GB; Paoletti AM
Contraception; 2009 Feb; 79(2):117-21. PubMed ID: 19135568
[TBL] [Abstract][Full Text] [Related]
9. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles.
Rabe T; Hartschuh E; Wahlstrom T; Höschen K; König S
Contraception; 2010 Oct; 82(4):358-65. PubMed ID: 20851230
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Scheffler MR; Colburn W; Kook KA; Thomas SD
Clin Pharmacol Ther; 1999 May; 65(5):483-90. PubMed ID: 10340913
[TBL] [Abstract][Full Text] [Related]
11. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial.
Cagnacci A; Ferrari S; Tirelli A; Zanin R; Volpe A
Contraception; 2009 Feb; 79(2):111-6. PubMed ID: 19135567
[TBL] [Abstract][Full Text] [Related]
12. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
Schramm G; Heckes B
Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women.
Schramm GA; Schrah G
Contraception; 2011 Oct; 84(4):390-401. PubMed ID: 21920195
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
Plewig G; Cunliffe WJ; Binder N; Höschen K
Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
[TBL] [Abstract][Full Text] [Related]
15. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
Anthuber S; Schramm GA; Heskamp ML
Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
[TBL] [Abstract][Full Text] [Related]
16. Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea.
Grandi G; Napolitano A; Xholli A; Tirelli A; Di Carlo C; Cagnacci A
Gynecol Endocrinol; 2015 Oct; 31(10):774-8. PubMed ID: 26291811
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
18. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
Blode H; Foidart JM; Heithecker R
Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
[TBL] [Abstract][Full Text] [Related]
19. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
20. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations.
Lello S; Primavera G; Colonna L; Vittori G; Guardianelli F; Sorge R; Raskovic D
Gynecol Endocrinol; 2008 Dec; 24(12):718-23. PubMed ID: 19172543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
